Determination of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry

被引：43

作者：

Kanazawa, H

Okada, A

Matsushima, Y

Yokota, H

Okubo, S

Mashige, F

Nakahara, K

机构：

[1] Kyoritsu Coll Pharmaceut Sci, Minato Ku, Tokyo 1058512, Japan

[2] Univ Tokyo, Dept Lab Med, Bunkyo Ku, Tokyo 1138655, Japan

来源：

JOURNAL OF CHROMATOGRAPHY A | 2002年 / 949卷 / 1-2期

关键词：

sonic spray ionization; interfaces; LC-MS; omeprazole; cytochromes; benzimidazoles;

D O I：

10.1016/S0021-9673(01)01508-4

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Omeprazole is a benzimidazole compound that acts as a proton-pump inhibitor. Because the metabolism of omeprazole is mainly catalyzed by cytochrome P-450 (CYP) 3A4 and CYP2C19, the genetic polymorphism of CYP2C19 could be of clinical concern in the treatment of acid-related diseases with omeprazole. Therefore, a reliable method for omeprazole phenotyping is desirable in clinical situations. This study has demonstrated the determination of omeprazoie and its metabolites in human plasma by liquid chromatography-three-dimensional quadrupole mass spectrometry with a sonic spray ionization interface. The analytical column was YMC-Pack Pro C-18(50X2.0 mm I.D.) using acetonitrile-50 mm ammonium acetate (pH 7.25) (1:4) at a flow-rate of 0.2 ml /min. The drift voltage was 30 V The sampling aperture was heated at 110 degreesC and Shield temperature was 230 degreesC. In the mass spectrum, the molecular ions of omeprazole, hydroxyomeprazole and omeprazole sulfone were clearly observed as base peaks. This method is sufficiently sensitive and accurate for pharmacokinetic studies of omeprazol. (C) 2002 Elsevier Science B V All rights reserved.

引用

收藏

页码：1 / 9

页数：9

相关论文

共 23 条

[11] Determination of sedatives and anesthetics in plasma by liquid chromatography mass spectrometry with a desalting system [J].

Kanazawa, H ;

Konishi, Y ;

Matsushima, Y ;

Takahashi, T .

JOURNAL OF CHROMATOGRAPHY A, 1998, 797 (1-2) :227-236

[12] DETERMINATION OF MEDETOMIDINE, ATIPAMEZOLE MIDAZOLAM IN PIG PLASMA BY LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY [J].

KANAZAWA, H ;

NISHIMURA, R ;

SASAKI, N ;

TAKEUCHI, A ;

TAKAI, N ;

NAGATA, Y ;

MATSUSHIMA, Y .

BIOMEDICAL CHROMATOGRAPHY, 1995, 9 (04) :188-191

[13] LIQUID-CHROMATOGRAPHY MASS-SPECTROMETRY FOR THE DETERMINATION OF MEDETOMIDINE AND OTHER ANESTHETICS IN PLASMA [J].

KANAZAWA, H ;

NAGATA, Y ;

MATSUSHIMA, Y ;

TAKAI, N ;

UCHIYAMA, H ;

NISHIMURA, R ;

TAKEUCHI, A .

JOURNAL OF CHROMATOGRAPHY, 1993, 631 (1-2) :215-220

[14] Determination of theophylline and its metabolites in biological samples by liquid chromatography-mass spectrometry [J].

Kanazawa, H ;

Atsumi, R ;

Matsushima, Y ;

Kizu, J .

JOURNAL OF CHROMATOGRAPHY A, 2000, 870 (1-2) :87-96

[15] SIMULTANEOUS DETERMINATION OF OMEPRAZOLE AND ITS METABOLITES IN PLASMA AND URINE BY REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH AN ALKALINE-RESISTANT POLYMER-COATED C18 COLUMN [J].

KOBAYASHI, K ;

CHIBA, K ;

SOHN, DR ;

KATO, Y ;

ISHIZAKI, T .

JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 579 (02) :299-305

[16] Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population [J].

Kubota, T ;

Chiba, K ;

Ishizaki, T .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (06) :661-666

[17] No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects [J].

Laine, K ;

Tybring, G ;

Bertilsson, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (02) :151-159

[18] The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin [J].

Sarich, T ;

Kalhorn, T ;

AlSayegh, F ;

Adams, S ;

Slattery, J ;

Goldstein, J ;

Nelson, S ;

Wright, J .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (01) :21-28

[19] Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population [J].

Sviri, S ;

Shpizen, S ;

Leitersdorf, E ;

Levy, M ;

Caraco, Y .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (03) :275-282

[20] Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype [J].

Tanaka, M ;

Ohkubo, T ;

Otani, K ;

Suzuki, A ;

Kaneko, S ;

Sugawara, K ;

Ryokawa, Y ;

Hakusui, H ;

Yamamori, S ;

Ishizaki, T .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (06) :619-628